Clinical Trial Update: Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis [Phase 2]

View source ↗

Summary

A Phase 2 randomized, double-blind study evaluating sparsentan (RE-021) for safety and efficacy in focal segmental glomerulosclerosis has completed and posted r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• Sparsentan (sparsentan)

Snippet

Sponsor: Travere Therapeutics, Inc. | Conditions: Focal Segmental Glomerulosclerosis | Phase 2 | Status: COMPLETED | Results posted: 2021-07-27